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Abstract
Objective: Adiponectin, an adipokine with profound
insulin-sensitizing effect, consists of heterogeneous spe-
cies of multimers. These oligomeric complexes circulate
as low-molecular-weight (LMW) trimers, medium-mole-
cular-weight (MMW) hexamers and high-molecular-
weight (HMW) isoforms and can exert differential
biological effects. The aims of this study were to deter-
mine whether there is a change in circulating adiponectin
multimers in the presence of gestational diabetesmellitus
(GDM), overweight/obesity or with a treatment with sul-
fonylurea or insulin in patients with GDM.
Study design: This cross-sectional study included
women with: 1) normal pregnancy (ns149); and 2)
patients with GDM (ns72). Thirty-three patients with
GDM were managed with diet alone. Among the others
39 diabetic patients, 17 were treated with Glyburide and
22 with insulin. The study population was further strati-
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fied by first trimester body mass index (BMI) (normal
weight -25 kg/m2 vs. overweight/obese G25 kg/m2).
Serum adiponectin multimers (total, HMW, MMW and
LMW) concentrations were determined by ELISA.
Results: 1) The median maternal serum of total, HMW,
MMW and LMW were lower in patients with GDM than
in those with normal pregnancies (P-0.001 for all com-
parisons); 2) patients with GDM had a lower HMW/total
adiponectin ratio and a higher MMW/total and LMW/total
adiponectin ratio than those with a normal pregnancy
(P-0.001 for all comparisons); and 3) among GDM
patients, there were no differences in the concentra-
tions and relative distribution of adiponectin multimers
between those who were managed with diet, and those
who were treated with pharmacological agents.
Conclusion: 1) GDM is characterized by a distinctive
pattern of concentrations and relative distribution of adi-
ponectin multimers akin to Type 2 diabetes mellitus;
2) dysregulation of adiponectin multimeres can provide a
mechanistic basis for the association between adiposity
and GDM.
Keywords: Adipokines; body mass index (BMI); diabe-
tes; gestational diabetes; high-molecular-weight (HMW)
adiponectin; low-molecular-weight (LMW) adiponectin;
medium-molecular-weight (MMW) adiponectin; obesity;
overweight; pregnancy.
Introduction
Gestational diabetes mellitus (GDM), defined as a car-
bohydrate intolerance of varying severity with onset or
first recognition during pregnancy w6, 42, 91, 102x, affects
1–10% of all pregnancies w4, 5, 12, 24, 33, 67x. Several
features of GDM make this common complication of
pregnancy of special importance: 1) it is associated with
an increased rate of short-term complications for the
mother (e.g., cesarean section, and preeclampsia) w54,
70, 119, 129x, the fetus (e.g., macrosomia, perinatal mor-
tality) w122, 127x, and the neonate (e.g., brachial plexus
injury, hypoglycemia) w54, 55, 108, 120, 122, 127, 129,
148x; 2) weight reduction, exercise w19, 56x, oral hypo-
glycemic agents and insulin w28, 68, 69, 121, 140x
improve metabolic indices and reduce the rate of mater-
nal, fetal and neonatal complications; 3) GDM is asso-
ciated with long-term morbidity and mortality for the
mothers (Type 2 diabetes mellitus, cardiovascular dis-
638 Mazaki-Tovi et al., Adiponectin multimers in gestational diabetes
Article in press - uncorrected proof
ease) w2, 14, 20, 21, 32, 45, 60, 63, 109, 124x and their
infants (childhood obesity, metabolic syndrome) w7, 17,
30, 110x; and 4) the prevalence of this metabolic com-
plication is constantly increasing w36, 143x.
Recently, adipose tissue has emerged as an important
endocrine organ via the production of adipokines. Fur-
thermore, dysregulation of adipokine production and/or
secretion has been implicated in Type 2 DM. Indeed,
polymorphisms of several adipokines such as adiponec-
tin w38, 44, 53, 71, 90, 96, 131x, resistin w89, 104x, visfatin
w153x, and leptin receptor w123x are associated with insu-
lin resistance and Type 2 DM. Moreover, compared to
non-diabetic individuals, patients with Type 2 DM have
higher circulating concentrations of resistin w41, 88, 151x,
TNF-a w31, 92x, RBP-4 w25, 150x and CRP w37, 111x, as
well as lower concentrations of adiponectin w51, 61, 112,
145x. These findings laid the groundwork for the hypoth-
esis that perturbation of adipokine homeostasis has also
a role in the pathophysiology of gestational diabetes.
Adiponectin, an adipokine produced exclusively and
abundantly by adipocytes, is the most abundant gene
(AMP1) product of adipose tissue w52, 74, 94, 125x, and
circulates at high concentrations in the plasma w59x.
Unlike other adipokines, adiponectin concentrations are
negatively correlated with adiposity w8, 52x, suggesting
that adipose tissue exerts a negative feedback on adi-
ponectin production and/or secretion. Adiponectin has
insulin sensitizing w13, 26, 40, 75, 98, 135, 149x and anti-
inflammatory w126x properties, thus providing a mecha-
nistic molecular basis for the association between an
excess fat depot and obesity-related complication
including Type 2 DM. Adiponectin is secreted from adi-
pocytes and circulates in the plasma in distinct forms: 1)
low-molecular-weight (LMW) trimers; 2) medium-mole-
cular-weight (MMW) hexamers; and 3) high-molecular-
weight (HMW) oligomers (12–18 subunits) w9, 16, 105,
138, 139, 144x. A growing body of evidence suggests
that the different isoforms exert differential biological
effects w9, 16, 64, 105, 106, 144x. Specifically, the anti-
diabetogenic properties of adiponectin have been attrib-
uted to the HMW isoforms w11, 39, 47, 58, 64, 95, 106,
133, 136, 144x.
Data regarding circulating maternal adiponectin multi-
mers concentrations in human pregnancy are limited w23,
35, 77, 103, 115, 116, 132x. Indeed, only one study has
reported the concentration of HMW adiponectin in
patients with GDM. To date there are no reports con-
cerning the concentrations and relative distribution of
MMW or LMW. Moreover, there are no data regarding the
relationship between overweight/obesity and adiponectin
multimers in patients with GDM. Thus, the aims of this
study were to determine whether: 1) there is a change in
adiponectin multimers concentrations in the presence of
GDM or overweight/obesity; and 2) treatment with a
sulfonylurea (Glyburide) or insulin is associated with a
change in the concentrations of adiponectin and its
multimers.
Materials and methods
Study groups and inclusion criteria
A cross-sectional study was conducted including patients in
the following groups: 1) normal pregnant women (ns149);
and 2) patients with GDM (ns72). The study population was
further stratified by first trimester body mass index (BMI) (normal
weight 18.5–24.9 kg/m2 vs. overweight/obese G25 kg/m2).
Maternal serum and clinical data were obtained from our bank
of biological samples and clinical databases. Many of these
samples have been previously employed to study the biology of
inflammation, angiogenesis regulation, and growth factor con-
centrations in normal pregnant women and in those with preg-
nancy complications.
Written informed consent was obtained from all participants
after approval by the Institutional Review Boards of the Sotero
del Rio Hospital (Santiago, Chile), Wayne State University
(Detroit, MI, USA) and the Eunice Kennedy Shriver National Insti-
tute of Child Health and Human Development (NICHD; Bethes-
da, MD, USA).
Clinical definitions
The inclusion criteria for normal pregnant women were: singleton
gestation, no prior diabetes mellitus, no maternal or fetal com-
plications during pregnancy, normal plasma glucose concentra-
tions in the first trimester, normal oral glucose challenge test,
and delivery at term of a healthy neonate with a birthweight
above the 10th percentile for gestational age.
All patients were screened for GDM with a 1-h, 50-g oral glu-
cose challenge test. Pregnant women with plasma glucose con-
centrations G135 mg/dL at 1 h underwent a 100-g oral glucose
tolerance test (OGTT). Women with two or more abnormal plas-
ma glucose values were given a diagnosis of GDM w2, 22x.
Patients with gestational diabetes were excluded from the study
if they had pregestational diabetes mellitus, collagen vascular
diseases, inflammatory bowel disease and chronic inflammatory
conditions, or if they were using corticosteroids.
Maternal assessment and treatment of patients
with gestational diabetes
All women diagnosed with GDM were given nutritional instruc-
tions for three meals and four snacks daily and individualized
dietary advice from a qualified dietitian. Compliance with the
dietary regimen was evaluated weekly during visits to the high-
risk clinic. The diets were designed to provide 25 kcal/kg of body
weight for obese women and 35 kcal/kg for lean women, with
40–45% of the calories from carbohydrates w2, 3x.
A nurse educator instructed the women in how to measure
blood glucose with a glucometer. The patients were asked to
measure capillary blood glucose four times daily: after an over-
night fast, and 2 h after each meal w68x. The goals of treatment
were a fasting blood glucose concentration of 60–90 mg/dL and
a postprandial blood glucose concentration of -120 mg/dL
w50x. If the blood glucose values of the patient treated with diet
did not meet the goals for a two-week period the patient
received a starting dose of 2.5 mg Glyburide orally in the morn-
ing. A physician evaluated the blood glucose values at each visit,
and increased the Glyburide dose as needed to meet these
goals. The dose of Glyburide was increased the following week
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Table 1 Clinical and demographic characteristics of the study population.
Normal pregnancy Gestational diabetes mellitus P-value
(ns149) (ns72)
Maternal age (years) 25.0 (21.0–31.0) 27.0 (23.0–33.0) 0.1
Ethnic origin
African American 58 (80.6%) 110 (73.8%) 0.1
Hispanic 8 (11.1) 29 (19.5%) 0.2
Caucasian 4 (5.5%) 8 (5.3%) 0.9
Others 2 (2.7%) 2 (1.3%) 0.4
First trimester BMI (kg/m2) 24.0 (22.0–26.2) 30.6 (24.5–36.6) -0.001
BMI at blood sampling (kg/m2) 30.0 (27.7–33.3) 35.3 (29.8–41.5) -0.001
BMI difference between blood sampling and 5.6 (4.4–7.2) 4.5 (3.0–6.1) 0.3
the first trimester
Gestational age at sampling (weeks) 37.6 (32.8–40.2) 37.6 (33.4–39.0) 0.1
Gestational age at delivery (weeks) 39.8 (39.0–40.2) 38.2 (36.8–39.2) 0.07
Birth weight (g) 3285 (2862–3687) 3440 (3210–3670) 0.018
Values are expressed as median (interquartile range); BMI, body mass index.
by 2.5 mg and thereafter by 5 mg weekly up to a total of 20 mg
daily when necessary w66x. If the blood glucose values of a wom-
an treated with the maximal dose of Glyburide did not meet the
goals for a two-week period, the treatment was switched to
insulin therapy. The starting dose for insulin was 0.7 U/kg of
actual body weight at admission, given subcutaneously three
times daily and increased weekly as necessary w68x.
The BMI was calculated according to the formula: weight (kg)/
height (m2). Normal weight women were defined as those with
BMI of 18.5–24.9 kg/m2 according to the definitions of the World
Health Organization (WHO) w1x. Pregnant women were classified
by their first trimester BMI into two groups: normal weight and
overweight/obese (BMIG25 kg/m2).
Maternal blood samples were collected with a vacutainer
directly into tubes. Samples were centrifuged and the sera were
stored at –808C until analysis. Sensitive enzyme-linked immu-
noassays were used to determine the concentrations of adipo-
nectin multimeric forms in maternal serum. Immunoassays were
purchased from ALPCO Diagnostics (Salem, NH, USA). The
assays were run according to the manufacturer’s recommen-
dations. To detect HMW adiponectin, serum samples were pre-
treated with a specific protease that selectively digested MMW
and LMW adiponectin. We were also able to determine the com-
bined HMW and MMW adiponectin concentrations by retreating
the samples with a protease that specifically digested LMW adi-
ponectin. Maternal serum samples were assayed directly to
determine total adiponectin concentrations. Briefly, untreated
and pre-treated maternal serum samples were incubated in
duplicate wells of the micro titer plates, which had been pre-
coated with a monoclonal antibody specific for adiponectin. Dur-
ing this incubation any adiponectin present in the standards and
untreated or pre-treated maternal serum samples was bound by
the immobilized antibodies. After repeated washing and aspi-
ration to remove all unbound substances, an enzyme-linked
polyclonal antibody specific for adiponectin was added to the
wells. Unbound materials were removed with repeated washing
and a substrate solution was added to the wells and color devel-
oped in proportion to the amount of adiponectin bound in the
initial step. The color development was stopped with the addi-
tion of an acid solution and the intensity of color was read using
a programmable spectrophotometer (SpectraMaxM2,Molecular
Devices, Sunnyvale, CA, USA). The concentration of adiponectin
in untreated and treated maternal serum samples was deter-
mined by interpolation from individual standard curves com-
posed of human adiponectin. Total, HMW, and HMW-MMW
adiponectin concentrations were derived directly from the assay
plates. MMW adiponectin concentrations were obtained by sub-
tracting the HMW adiponectin value from the combined HMW-
MMW value. Finally, the LMW adiponectin value was computed
by subtracting HMW and MMW adiponectin values from the
total adiponectin values. The calculated inter- and intra-assay
coefficients of variation for adiponectin multimers immunoas-
says in our laboratory were 2.2% and 4.2%, respectively. The
sensitivity was calculated to be 0.04 ng/mL.
Statistical analysis
Normality of data distribution was tested using the Shapiro–Wilk
or Kolmogorov-Smirnov tests. Since serum multimeric adipo-
nectin isoforms concentrations were not normally distributed,
Mann-Whitney U-test were used for comparisons of continuous
variables. Kruskal-Wallis test was used for the comparison of
normal pregnant women patients with diabetic patients with and
without pharmacologic treatment, as well as for the comparison
between normal weight and overweight pregnant women with
and without GDM. Comparison of proportions was performed
by x2 and Fisher’s exact tests. Multiple linear regression analysis
was used to determine which factors were significantly and
independently associated with maternal serum adiponectin iso-
forms as well as their relative distribution (after log transforma-
tion). The following parameters were included in the model:
maternal age, parity, gestational age at sampling, gestational
age at delivery, birth weight, first trimester BMI, difference in BMI
between first trimester and blood sampling, and the presence
of GDM. A P-Value-0.05 was considered statistically signifi-
cant. Analysis was performed with SPSS, version 14 (SPSS Inc.,
Chicago, IL, USA).
Results
Table 1 displays the demographic and clinical character-
istics of women with a normal pregnancy and those with
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Figure 1 Comparison of the median serum total, HMW, MMW
and LMW adiponectin concentrations between pregnant women
with normal pregnancies and those with GDM.
The median maternal serum concentration of total, HMW, MMW
and LMW were significantly lower in patients with GDM than in
those with normal pregnancies (P-0.001 for all comparisons).
GDM. Among patients with GDM, 33/72 were treated
with diet alone. Among the other 39 diabetic patients, 17
were treated with Glyburide and 22 with insulin. As
expected, patients with GDM had a higher first and third
trimester BMI and larger neonates. There were no signif-
icant differences in maternal age, gestational age at
blood sampling, gestational age at delivery and the dif-
ference in BMI between patients with a normal pregnan-
cy and those with GDM (Table 1). Table 2 displays the
demographic and clinical characteristics of the study
population according to BMI. There were no significant
differences in gestational age at blood sampling, gesta-
tional age at delivery and neonatal birthweight between
normal weight and overweight/obese women in both
groups (Table 2).
Adiponectin multimers concentrations and their
relative distribution in GDM vs. normal pregnancy
(non-GDM)
The median maternal serum concentration of total adi-
ponectin was lower in patients with GDM than those with
a normal pregnancy (median: 3022 ng/mL, interquartile
range (IQR) 2102–4204 vs. 6019 ng/mL, IQR 4596–8256;
P-0.001, Figure 1). Similarly, patients with GDM had a
lower median serum concentration of HMW (1203
ng/mL, IQR 593–1800 vs. 3297 ng/mL, IQR 2187–4657;
P-0.001, Figure 1), MMW (881 ng/mL, IQR 639–1259
vs. 1394 ng/mL, IQR 993–1839; P-0.001, Figure 1), and
LMW adiponectin (968 ng/mL, IQR 782–1218 vs.
1236 ng/mL, IQR 818–1724; P-0.001, Figure 1) than
those with a normal pregnancy.
The median maternal HMW/total adiponectin ratio was
lower in patients with GDM than those with a normal
pregnancy (0.37, IQR 0.27–0.45 vs. 0.54, IQR 0.47–0.62;
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Figure 2 Comparison of HMW/total adiponectin MMW/total
adiponectin and LMW/total adiponectin ratios between pregnant
women with normal pregnancies and those with GDM.
The median maternal HMW/total adiponectin ratio was lower in
patients with GDM than in those with a normal pregnancy. In
contrast, patients with GDM had a higher median MMW/total
adiponectin and LMW/total adiponectin ratios than those with a
normal pregnancy.
P-0.001, Figure 2). In contrast, patients with GDM had
a higher median MMW/total adiponectin ratio (0.30, IQR
0.26–0.35 vs. 0.23, IQR 0.16–0.29; P-0.001, Figure 2),
and a higher LMW/total adiponectin ratio (0.32, IQR
0.25–0.39 vs. 0.21, IQR 0.15–0.28; P-0.001, Figure 2)
than those with a normal pregnancy.
Adiponectin multimers concentrations and their
relative distribution in GDM: normal weight vs.
overweight/obesity
Among patients with GDM, women with normal weight
and those with overweight/obesity did not differ in the
median serum concentration of total adiponectin
(3731 ng/mL, IQR 2218–5809 vs. 2848 ng/mL, IQR
2070–4092, respectively; Ps0.13, Figure 3A), HMW adi-
ponectin (1315 ng/mL, IQR 679–3239 vs. 1168 ng/mL,
IQR 570–1645, respectively; Ps0.12, Figure 3B), MMW
adiponectin (1071 ng/mL, IQR 650–1271 vs. 858 ng/mL,
IQR 625–1218, respectively; Ps0.21, Figure 3C), and
LMW adiponectin (1001 ng/mL, IQR 746–1291 vs.
951 ng/mL, IQR 785–1218, respectively; Ps0.97, Figure
3D).
Similar to women with a normal pregnancy, among
patients with GDM, patients with normal weight and
those with overweight/obesity had a comparable median
ratio of HMW/total adiponectin (0.39, IQR 0.29–0.52 vs.
0.36, IQR 0.27–0.43; Ps0.1, Figure 4A), MMW/total
adiponectin (0.30, IQR 0.21–0.36 vs. 0.30, IQR 0.27–
0.35, respectively; Ps0.5, Figure 4B), and LMW/total
adiponectin (0.29, IQR 0.17–0.38 vs. 0.33, IQR
0.28–0.33; Ps0.2, Figure 4C).
Adiponectin multimers concentrations and their
relative distribution in normal weight pregnant
women: normal pregnancy (non-GDM) vs. GDM
Among patients with a normal weight, women with a nor-
mal pregnancy had a higher median serum concentration
of total (6987 ng/mL, IQR 5051–8713 vs. 3731 ng/mL,
IQR 2218–5809; P-0.001, Figure 3A), HMW (3916
ng/mL, IQR 2536–5169 vs. 1315 ng/mL, IQR 679–3239;
P-0.001, Figure 3B), MMW (1446 ng/mL, IQR
1021–1914 vs. 1071 ng/mL, IQR 650–1271; Ps0.005,
Figure 3C) and LMW adiponectin (1236 ng/mL, IQR
916–2052 vs. 1001 ng/mL, IQR 746–1291; Ps0.01,
Figure 3D) than those with GDM.
Among patients with a normal weight, women with a
normal pregnancy had a higher HMW/total adiponectin
ratio than those with GDM (0.55, IQR 0.49–0.63 vs. 0.39,
IQR 0.29–0.52; P-0.001, Figure 4A). In contrast, MMW/
total ratio (0.23, IQR 0.16–0.28 vs. 0.30, IQR 0.21–0.36;
Ps0.007, Figure 4B) and LMW/total adiponectin ratio
(0.21, IQR 0.15–0.28 vs. 0.29, IQR 0.17–0.38; Ps0.013,
Figure 4C) were lower in women with a normal pregnancy
than those with GDM.
Adiponectin multimers concentrations and their
relative distribution in overweight/obese pregnant
women: normal pregnancy (non-GDM) vs. GDM
Among patients with overweight/obesity, women with a
normal pregnancy had a higher median serum concen-
tration of total (5207 ng/mL, IQR 4291–7095 vs. 2848
ng/mL, IQR 2070–4092; P-0.001, Figure 3A), HMW
(2733 ng/mL, IQR 2118–3733 vs. 1168 ng/mL, IQR
570–1645; P-0.001, Figure 3B), MMW (1330 ng/mL,
IQR 788–1683 vs. 858 ng/mL, IQR 625–1218; P-0.001,
Figure 3C), and LMW adiponectin (1237 ng/mL, IQR
813–1649 vs. 951 ng/mL, IQR 785–1218; Ps0.02, Fig-
ure 3D) than those with GDM.
Among patients with overweight/obesity, women with
a normal pregnancy had a higher HMW/total adiponectin
ratio than those with GDM (0.54, IQR 0.45–0.61 vs. 0.36,
IQR 0.27–0.43; P-0.001, Figure 4A). In contrast, MMW/
total ratio (0.23, IQR 0.16–0.29 vs. 0.30, IQR 0.27–0.35;
P-0.001, Figure 4B) and LMW/total adiponectin ratio
(0.21, IQR 10.5–0.28 vs. 951 ng/mL, IQR 785–1218;
P-0.001, Figure 4C) were lower in overweight/obese
women with a normal pregnancy than those with GDM.
Adiponectin multimers concentrations and their
relative distribution in patients with GDM: the effect
of pharmacologic treatment
Patients with GDM who were managed with diet and
those treated with a pharmacologic agent (Glyburide or
insulin) had comparable concentrations of total adipo-
nectin (2811 ng/mL, IQR 2077–3874 vs. 3454 ng/mL,
IQR 2130–4613, respectively; Ps0.2). Similarly, median
642 Mazaki-Tovi et al., Adiponectin multimers in gestational diabetes
Article in press - uncorrected proof
Figure 3 Maternal serum total adiponectin (A), HMW adiponectin (B), MMW adiponectin (C) and LMW adiponectin (D) concentrations
in women with a normal pregnancy and those with GDM according to first trimester BMI (normal weight vs. overweight/obese).
Among patients with a normal pregnancy, the median serum concentration of total and HMW adiponectin were higher in women with
normal weight than in those with overweight/obesity. Among patients with GDM, women with normal weight and those with over-
weight/obesity did not differ in the median serum concentrations of total, HMW, MMW and LMW adiponectin. Among patients with
overweight/obesity, women with a normal pregnancy had higher median serum concentrations of total, HMW, MMW and LMW
adiponectin (Ps0.020) than those with GDM.
maternal serum concentrations of HMW, MMW and LMW
adiponectin did not differ significantly between the two
groups. The relative distribution of adiponectin isoforms
was also comparable between the two groups. Similarly,
there were no differences in the concentrations and
relative distribution of adiponectin multimers between
patients who were treated with Glyburide and those who
were treated with insulin.
Multiple regression analysis was employed to examine
the contribution of the presence of GDM on the serum
concentration of adiponectin isoforms, while adjusting for
maternal age, maternal BMI (normal weight vs. over-
weight/obese), the difference in BMI between the third
and the first trimester, gestational age at blood sampling,
and birthweight. The final regression model suggested
that the presence of GDM and first trimester BMI were
independently associated with decreased maternal
serum total adiponectin (P-0.001 and 0.031, respective-
ly), and HMW adiponectin concentrations (P-0.001 and
0.009, respectively), as well as with decreased HMW/
total adiponectin ratio (P-0.001 and 0.02, respectively).
Discussion
Principal findings of the study
1) The median maternal serum of total, HMW, MMW and
LMW were lower in patients with GDM than in those with
a normal pregnancy; 2) patients with GDM had a lower
Median HMW/total adiponectin ratio and a higher MMW/
total and LMW/total adiponectin ratio than those with a
normal pregnancy; 3) among patients with GDM, median
maternal serum concentrations of adiponectin multimers
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Figure 4 Comparison of HMW/total adiponectin (A) MMW/total
adiponectin (B) and LMW/total adiponectin (C) ratios between in
women with a normal pregnancy and those with GDM according
to first trimester BMI (normal weight vs. overweight/obese).
Women with normal weight and those with overweight/obesity
did not differ in the median ratio of HMW/total adiponectin,
MMW/total adiponectin and LMW/total adiponectin. Similarly,
among patients with GDM, these ratios were comparable
between patients with normal weight and those with overweight/
obesity. Overweight/obese women with a normal pregnancy had
a higher HMW/total adiponectin ratio than those with GDM. In
contrast, the MMW/total adiponectin and LMW/total adiponectin
ratios were lower in overweight/obese pregnant women with a
normal pregnancy than in those with GDM.
and their relative distribution did not differ between
women with normal weight and those with overweight/
obesity; 4) the presence of GDM was independently
associated with low maternal serum of total and HMW
adiponectin concentration as well as with decreased total
adiponectin, HMW adiponectin and HMW/total adipo-
nectin ratio; and 5) among GDM patients, there were no
differences in the concentrations and relative distribution
of adiponectin multimers between patients who were
managed with diet, and those who were treated with
pharmacological agents (Glyburide or insulin).
The role of adiponectin in obesity-related
complications of pregnancy
Recently, adipokines have been implicated in physiologic
adaptation of normal and complication of pregnancy w65,
77–86, 99–101, 141x. Indeed, the unique properties of
adiponectin have prompted many investigators to
explore the role of maternal circulating adiponectin in the
metabolic adaptations occurring during human pregnan-
cy w23, 82, 87x, as well as in obesity-related complica-
tions of pregnancy such as GDM w62, 114, 134, 147x and
preeclampsia w27, 29, 48, 49, 57, 73, 97, 113x. Indeed,
normal pregnancy is associated with alterations in mater-
nal circulating adiponectin w80, 82, 84, 128x and with
changes in the relative distribution of its isoforms w23, 77,
115, 116x. In addition, even in the presence of a normal
pregnancy, overweight pregnant women have a lower
adiponectin concentration than those with a normal
weight w43x. Moreover, low concentrations of adiponectin
in the first or early second trimester is an independent
risk factor for the development of GDM. Indeed, maternal
adiponectin concentration F6.4 mg/mL at 13 weeks of
gestation is associated with a 4.6-fold increased risk to
develop GDM later in pregnancy w146x, suggesting a
causal relationship between low circulating adiponectin
and GDM. Consistent with this finding, GDM is charac-
terized by a low circulating concentrations of adiponectin
w10, 62, 114, 117, 118, 134, 137, 147x. Collectively, a
growing body of evidence points to a key role of adipo-
nectin in the pathophysiology of both Type 2 DM and
GDM.
An asymmetrical decrease in adiponectin multimers
concentrations and alteration in their relative
distribution are features of gestational diabetes
The findings of the present study characterize GDM as a
condition in which there is a decrease in the maternal
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serum concentrations of all adiponectin multimers. In
addition, there is a concomitant decrease in the HMW/
total adiponectin ratio and increases in MMW/total as
well as LMW/total adiponectin ratios in patients with
GDM. These findings are novel. Only one study has
reported the concentrations of HMW adiponectin in
patients with GDM w115x. The lower median maternal
serum HMW concentration and HMW/total adiponectin
ratio in patients with GDM than those with a normal preg-
nancy, reported herein, are in agreement with the findings
of Retnakaran et al. w115x The present report extends
these observations by demonstrating that the maternal
concentrations of all adiponectin isoforms are decreased
and that MMW/total and LMW/total ratios are increased
in patients with GDM. Despite the fact that the decrease
in adiponectin multimers was across the board, only
HMW/total adiponectin ratio was lower in these patients
compared with normal pregnant women, indicating that
the decrease in HMW adiponectin was far more signifi-
cant than the reduction in the concentrations of MMW or
LMW isoforms. Indeed, MMW/total adiponectin and
LMW/total adiponectin ratios were higher in patients with
GDM than in those with a normal pregnancy. In conclu-
sion, the results of this study clearly reveal that the low
concentration of adiponectin in patients with GDM
should be attributed to an accentuated decrease in HMW
adiponectin.
Why is gestational diabetes associated with a
disparate decrease of adiponectin multimeric
complexes and their relative concentrations?
The findings regarding the asymmetrical decrease in adi-
ponectin multimers and their relative concentrations
reported herein support the emerging concept that the
anti-diabetic effect of adiponectin may be mediated by
the HMW isoforms. The cross sectional nature of the
present study limits our ability to infer a causal relation-
ship between adiponectin and GDM; however, the robust
association of low circulating total and HMW adiponectin
with states of insulin resistance has raised the possibility
that there may be a cause and effect relationship
between adiponectin and both Type 2 DM and GDM.
Several lines of evidence suggest a causal linkage
between the two: 1) treatment of adipose like cell lines
(3T3-L1 cells) with peroxisome proliferator-activated
receptor-g agonist (Thiazolidinediones) results in increas-
ed adiponectin expression w76x; 2) in vivo, exposure of
normal or obese mice to adiponectin increases insulin
sensitivity w13, 40, 149x; 3) mutations in the adiponectin
gene that result in failure to form HMW adiponectin (e.g.,
G84R and G90S) are associated with Type 2 DM and low
adiponectin concentrations w144x. Similarly, polymor-
phisms in the adiponectin gene increase susceptibility to
develop metabolic syndrome and Type 2 DM w38, 44, 46,
53, 71, 90, 96, 131, 142x and; 4) low adiponectin con-
centrations confer an increased risk for the development
of Type 2 DM even in the absence of any other biomar-
kers of impaired glucose metabolism w72, 130x.
In conclusion, the findings reported herein define dys-
regulation of adipose tissue as a feature of GDM. It is
tempting to postulate that the decrease in adiponectin
multimeric complexes concentrations and their relative
distribution can lead to modulation of adiponectin effect
on target tissues (i.e., muscles, liver, adipose tissue), thus
providing a mechanistic basis to GDM.
Gestational diabetes and overweight/obesity – an
ominous metabolic combination
The finding that adiponectin multimers and their relative
concentrations are comparable between normal weight
and overweight/obese patients with GDM is novel. The
negative association between circulating adiponectin and
excess adipose tissue accrual is well established w8, 77x.
However, while overweight/obesity and weight gain usu-
ally mitigates adiponectin concentrations, we found no
significant change in the concentrations of adiponectin
multimers between normal weight and overweight/obese
patients in the presence of GDM. Thus, it can be con-
cluded that the effect of obesity on the quantitative and
qualitative alterations in adiponectin multimers in obese
pregnant women is overwhelmed by the presence of
GDM. The fact that the median maternal serum concen-
trations of all adiponectin multimers were lower in over-
weight/obese patients with GDM than in overweight/
obese individuals with a normal pregnancy further sup-
ports this hypothesis. Of interest, among overweight/
obese subjects, the decrease in HMW adiponectin was
disproportionate in patients with GDM as indicated by a
lower median HMW/total adiponectin ratio in patients
with GDM than that of those with a normal pregnancy
and higher median MMW/total and LMW/total adiponec-
tin ratios.
Previous reports demonstrate that higher order adi-
ponectin multimers do not interconvert in the circulation.
Thus, the quantitative and qualitative changes in adipo-
nectin multimers reported herein must be attributed to
altered production/secretion by adipocytes. Hence, it can
be concluded that GDM is characterized by adipose tis-
sue dysfunction as manifested by dysregulation of cir-
culating adiponectin multimers. This finding may have
clinical implications since manipulation of adiponectin
concentrations and the relative distribution of its multi-
meric complexes opens new avenues for the treatment
of Type 2 DM, as well as GDM.
Diet, sulfonylurea and insulin and adiponectin
multimers concentrations and their abundance
There was no difference in the concentrations of adipo-
nectin isoforms or their relative distribution between
patients who were managed with diet and those who
were treated with Glyburide or insulin. Similarly, patients
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treated with Glyburide and those treated with insulin had
comparable concentrations of adiponectin multimers.
These findings are novel. Indeed, there are no reports
concerning the effect of sulfonylurea exposure on adi-
ponectin concentrations during pregnancy; thus, the
present study is the first to compare circulating adipo-
nectin and adiponectin multimers in pregnant women
with and without sulfonylurea treatment. The literature
regarding the effect of insulin on adiponectin is contro-
versial. Insulin’s inhibitory effect on adiponectin gene
expression has been demonstrated in vitro w34x. In accor-
dance with this finding, a 10–20% reduction in adipo-
nectin concentrations was reported in several hyper-
insulinemic-euglycemic clamp studies in lean humans
w18, 93, 152x. In contrast, other investigators found no
effect of insulin on circulating adiponectin w107x. Impor-
tantly, contradictory reports concerning the effect of
insulin on adiponectin multimers have been published.
Selective decreases in HMW w11x as well as no changes
in circulating concentrations of this isoforms w15x were
reported. A possible explanation for the lack of insulin
effect on adiponectin concentrations is that the inhibitory
effect of insulin on adiponectin is not dose depended. In
other words, once insulin reaches a certain concentration
it cannot exert any additional inhibitory effect on adipo-
nectin w15x. Since hyperinsulinemia is a characteristic of
GDM, supplementation with insulin may not be accom-
panied by a reduction in adiponectin concentrations as
insulin has already exerted its maximal inhibitory effect.
Only one study, by Catalano et al. w23x determined the
effect of insulin on adiponectin concentrations in a lon-
gitudinal study of lean pregnant women. Interestingly, the
authors reported that insulin infusion decreased HMW
adiponectin complexes in pregravid women but this sup-
pressive effect of insulin was lost during pregnancy. The
result of this study supports the report by Catalano et al.
and extends it by demonstrating comparable maternal
circulating adiponectin in patients with lean and over-
weight/obese patients with GDM. Congruent with this
observation, we found no difference between patients
who were treated with insulin and those who were man-
aged with diet alone.
In conclusion, perturbation of adiponectin homeostasis
and alterations in the relative distribution of its multimers
are considered to be a marker of adipose tissue function
since adiponectin is produced and modified exclusively
by adipocytes. Evaluation of adiponectin isoforms in nor-
mal weight and overweight/obese patients with GDM
reveals that this condition is characterized by a distinc-
tive pattern of concentrations and a relative distribution
of adiponectin multimers akin to Type 2 DM. Taken
together, the results of the present study suggest that
dysregulation of adiponectin multimers can provide a
mechanistic basis for the association between adiposity
and GDM. Moreover, the pattern of circulating adiponec-
tin multimers concentrations and their relative abundance
is congruent for both GDM and Type 2 DM. This finding
suggests that adiponectin dysregulation can account for
the long-term complication of GDM. Further studies are
needed in order to elucidate the intriguing relationships
between adiponectin multimers, GDM and the subse-
quent development of Type 2 DM.
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